Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyQualChoice elinzanetant (Lynkuet) Coverage Prior A…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PMN.304

    Elinzanetant (Lynkuet) coverage

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PMN.304 alerts

    Get alerted when Policy CP.PMN.304 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for elinzanetant (Lynkuet) for treatment of moderate to severe vasomotor symptoms due to menopause for QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyElinzanetant (Lynkuet) coverage
    Policy CodePolicy CP.PMN.304
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis, age, prior estrogen failures or contraindication, and dosing within the 120 mg/day limit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    120 mg/daymaximum daily dose
    12 monthsapproval duration
    ≥18minimum age
    2 estrogen failuresstep therapy

    Coverage Criteria — Elinzanetant (Lynkuet)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial Therapy (Vasomotor Symptoms)

    Covered when ALL of the following are met:

    Initial Approval - Vasomotor Symptoms: 1. Diagnosis of vasomotor symptoms associated with menopause; 2. Age ≥ 18 years; 3. Failure of two formulary estrogen products (not contraceptives), unless contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed 120 mg (2 capsules) per day.120 mg/day

    For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395

    Continuation Therapy (Vasomotor Symptoms)

    Covered when ALL of the following are met:

    Continued Therapy - Vasomotor Symptoms: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria; or (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy (e.g., vasomotor symptom reduction); 3. If request is for a dose increase, new dose does not exceed 120 mg (2 capsules) per day.120 mg/day

    Refer to state specific addendums for continuity of care where applicable

    Other Indications

    Other indications (must meet 1 or 2):

    Other Indications - policy routing: 1. If the drug has undergone a label change within the last 6 months not yet reflected in this policy, follow the applicable no-coverage or non-formulary policy for the relevant line of business as listed in the policy (see CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16 as applicable); 2. If the requested use (diagnosis, age, dosing) is NOT listed under Section III and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09, HIM.PA.154, CP.PMN.53).

    References to specific related policies provided in the policy document

    Non‑FDA approved indications that are not specifically addressed in this policy are excluded from coverage unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies. Refer to CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), and CP.PMN.53 (Medicaid) for the documentation standards and evidence requirements needed to consider coverage for off‑label uses.

    Pregnancy is a contraindication to use of elinzanetant; the drug is listed as contraindicated in pregnant individuals and should not be prescribed or authorized for members who are pregnant.

    Use of elinzanetant for non‑FDA approved indications without adequate supporting documentation of efficacy and safety may be considered not medically necessary. Providers requesting coverage for off‑label uses must follow the referenced off‑label use policies and submit the clinical evidence required by those policies to justify medical necessity.

    Coding and Dosage Information

    inv-07: Maximum daily dose — 120 mg/day
    Maximum daily dose120 mg/day (maximum dose stated as 120 mg PO QD; policy specifies dose does not exceed 120 mg or 2 capsules per day)
    Per-dose formulationAvailable as 60 mg capsules (2 capsules = 120 mg)
    Initial therapy limitInitial approval criterion requires dose ≤ 120 mg (2 capsules) per day
    Continued therapy limitIf request is for dose increase, new dose must not exceed 120 mg/day

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization requires documentation of meeting all approval criteria

    Prior authorization requests must include evidence that the member meets all initial approval criteria: diagnosis of vasomotor symptoms associated with menopause, age ≥ 18 years, documentation of prior estrogen failures or contraindication/intolerance (when applicable), and that the requested dose does not exceed 120 mg (2 capsules) per day.

    • Confirm diagnosis: vasomotor symptoms associated with menopause.
    • Confirm age: member is ≥ 18 years.
    • Document prior therapy: failure of two formulary estrogen products or documentation of contraindication/intolerance.
    • Confirm dosing: requested dose ≤ 120 mg/day (2 capsules).
    Step Therapy

    Failure of two formulary estrogens required before approval

    Approval for elinzanetant requires prior failure of two formulary estrogen products (excluding contraceptives) unless the member has a documented contraindication or clinically significant adverse effects; note Illinois HIM requests are exempt from step therapy per IL HB 5395 effective 1/1/2026.

    • Do not count contraceptives toward the two-formulary-estrogen requirement.
    • If contraindication or intolerance to estrogens is documented, step therapy may be bypassed.
    • For Illinois HIM requests dated on/after 1/1/2026, the step therapy requirement does not apply per IL HB 5395.
    Documentation Required

    Required clinical documentation must be submitted with PA

    Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other clinical information that demonstrates the member has met all approval criteria.

    • Include chart notes documenting diagnosis and symptom response.
    • Provide records of prior estrogen therapies and reasons for failure or contraindication.
    • Include dosing information to confirm the requested dose does not exceed 120 mg/day.
    Denial Risk

    Non‑FDA indications may be denied without sufficient evidence

    Requests for uses that are not FDA‑approved and not addressed in this policy may be denied unless sufficient documentation of efficacy and safety is provided per the referenced off‑label use policies.

    • If requesting a non‑FDA indication, include evidence of efficacy and safety consistent with off‑label use policies CP.CPA.09 (Commercial), HIM.PA.154 (Marketplace), or CP.PMN.53 (Medicaid).
    • Absence of adequate supporting documentation may result in denial or designation as not medically necessary.

    Background

    Elinzanetant is a neurokinin 1 and 3 receptor antagonist approved for treatment of moderate to severe vasomotor symptoms due to menopause. The approved dosing regimen is 120 mg orally once daily, supplied as 60 mg capsules; prior authorization and coverage decisions reference this approval context and dosing limit.

    Definitions

    inv-13: Elinzanetant (Lynkuet) definition and brief drug description
    Generic and brand nameElinzanetant (Lynkuet)
    Mechanism of actionNeurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist
    Indication (approved)For treatment of moderate to severe vasomotor symptoms due to menopause
    Dosage form and strengthCapsule, 60 mg; recommended dosing regimen 120 mg PO once daily (two 60 mg capsules)
    Maximum daily dose120 mg/day (documented dosing regimen and maximum in policy)
    Policy Summary
    PayerQualChoice
    PolicyElinzanetant (Lynkuet) coverage
    Policy CodePolicy CP.PMN.304
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis, age, prior estrogen failures or contraindication, and dosing within the 120 mg/day limit.
    SourceLink
    On This Page
    Coverage Criteria — Elinzanetant (Lynkuet)Coding and Dosage InformationProvider Actions and Prior AuthorizationBackgroundDefinitions